Abstract | OBJECTIVE: METHODS: BR was identified in patients after prostatectomy or radiation or both, with a PSA increase of ≥ 0.2 for prior prostatectomy or > 2 mg/dL increase for post-nadir in prior radiotherapy. CTCs were enumerated at baseline at the time of study entry using the CellSearch (Janssen Diagnostics, Raritan, NJ) test. RESULTS: The median age for all 36 patients accrued was 69.5 years (range, 51-91) with a median PSA of 1.65 ng/mL (range, 0.2-65.8). Gleason scores ranged from 5 to 9 (median, 7). The majority had prostatectomy (n = 25), external beam radiotherapy (n = 9), CyberKnife (Accuray, Sunnyvale, CA) (n = 1), and combined radiohormonal therapy (n = 1). PSADT ranged from 0.35 to 55 months, with a median of 7.43 months. The incidence of positive CTCs was 8.3% (3 patients), of whom 2 had biopsy-proven bony lesions on presenting with equivocal scans and PSADTs of 2.27 and 3.08 months, respectively. The third CTC-positive patient had a PSADT of 4.99 months. CONCLUSIONS: Obtaining CTCs in unselected patients presenting with BR has a relatively low yield. However, obtaining a positive CTC raises the suspicion of the presence of metastatic disease and may have utility for longitudinal follow-ups of patients with BR.
|
Authors | Jeanny B Aragon-Ching, Robert S Siegel, Harold Frazier 2nd, Ramez Andrawis, Frederick Hendricks, Michael Phillips, Thomas Jarrett, Hiwot Guebre-Xabiher, Steven Patierno, Samuel J Simmens |
Journal | Clinical genitourinary cancer
(Clin Genitourin Cancer)
Vol. 13
Issue 5
Pg. e341-5
(Oct 2015)
ISSN: 1938-0682 [Electronic] United States |
PMID | 25956468
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2015 Elsevier Inc. All rights reserved. |
Chemical References |
- Biomarkers, Tumor
- Prostate-Specific Antigen
|
Topics |
- Aged
- Aged, 80 and over
- Biomarkers, Tumor
(blood)
- Humans
- Male
- Middle Aged
- Neoplasm Grading
- Neoplasm Metastasis
- Neoplastic Cells, Circulating
(pathology)
- Prognosis
- Prostate-Specific Antigen
(blood)
- Prostatic Neoplasms
(blood, pathology, radiotherapy, surgery)
|